Dabrafenib mesylate

Key Product Details

Product Description

Dabrafenib mesylate is a potent and selective Raf kinase inhibitor (IC₅₀ values are 0.8, 3.2 and 5.0 nM for B-Raf^V600E, wild-type B-Raf and c-Raf, respectively). Exhibits selectivity for B-Raf over a panel of 270 other kinases. Arrests cell cycle in the G₁ phase and inhibits growth of B-Raf^V600E mutant melanoma and colon cancer cells in vitro and in vivo. Orally bioavailable. Also inhibits NEK9 (IC₅₀ <10 nM) and CDK16. Identified as targeting human host proteins that interact with SARS-CoV-2.

Product Specifications for Dabrafenib mesylate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Dabrafenib mesylate

The following data is based on the product molecular weight 615.66.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	3.25 mL	16.24 mL	32.49 mL
2.5 mM	0.65 mL	3.25 mL	6.50 mL
5 mM	0.32 mL	1.62 mL	3.25 mL
25 mM	0.06 mL	0.32 mL	0.65 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Gordon A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020 PMID: 32353859
• Rheault Discovery of Dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B.Raf-driven tumors. ACS Med Chem Lett 2013 PMID: 24900673
• Phadke Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol.Oncol. 2018 PMID: 29112787

Product Documents for Dabrafenib mesylate